Oncolytics Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. 

CEO
Jared Kelly
CEOJared Kelly
Employees
29
Employees29
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
29
Employees29

ONCY Key Statistics

Market cap
47.74M
Market cap47.74M
Price-Earnings ratio
-1.39
Price-Earnings ratio-1.39
Dividend yield
—
Dividend yield—
Average volume
1.32M
Average volume1.32M
High today
$0.4029
High today$0.4029
Low today
$0.34
Low today$0.34
Open price
$0.38
Open price$0.38
Volume
1.11M
Volume1.11M
52 Week high
$1.30
52 Week high$1.30
52 Week low
$0.3334
52 Week low$0.3334

Stock Snapshot

The current Oncolytics Biotech(ONCY) stock price is $0.37, with a market capitalization of 47.74M. The stock trades at a price-to-earnings (P/E) ratio of -1.39.

On 2026-11-20, Oncolytics Biotech(ONCY) stock traded between a low of $0.34 and a high of $0.40. Shares are currently priced at $0.37, which is +8.8% above the low and -8.2% below the high.

Oncolytics Biotech(ONCY) shares are trading with a volume of 1.11M, against a daily average of 1.32M.

In the last year, Oncolytics Biotech(ONCY) shares hit a 52-week high of $1.30 and a 52-week low of $0.33.

In the last year, Oncolytics Biotech(ONCY) shares hit a 52-week high of $1.30 and a 52-week low of $0.33.

ONCY News

TipRanks 7h
Oncolytics Biotech Stockholders Approve Annual Meeting Proposals

Oncolytics Biotech ( (ONCY) ) has provided an announcement. On November 19, 2026, the Company held its virtual annual meeting, with holders of 65,061,822 share...

TipRanks 2d
Oncolytics Biotech: Buy Rating Reaffirmed with Unchanged $5 Price Target Ahead of Key Pelareorep Trial Catalysts

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Oncolytics Biotech today and set a price target of $5.00. Patrick Trucchio gave his Buy rat...

TipRanks 6d
Oncolytics Biotech Faces Nasdaq Delisting Risk as Shares Trade Below $1 Threshold

Oncolytics Biotech (ONCY) has disclosed a new risk, in the Share Price & Shareholder Rights category. The analyst notes that Oncolytics Biotech faces a signifi...

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.